Neurology Medical News about Pituitary tumors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pituitary tumors
Current Treatment Options in Neurology, 06/02/09

Mathioudakis N et al. - Pituitary adenomas are the most common intrasellar tumors. With the exception of prolactinomas, first-line treatment is almost always surgical. Prolactinomas are usually treated with dopamine agonists such as cabergoline or bromocriptine. Somatostatin analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used as primary therapy in selected cases. Pegvisomant, a growth hormone receptor antagonist, is reserved for acromegalic patients who are resistant to treatment with somatostatin analogues. No effective medical therapy is available for adenomas that secrete adrenocorticotropic hormone, and occasionally bilateral adrenalectomy is required to resolve severe hypercortisolemia. Radiation therapy (fractionated or radiosurgery) can be used for residual or recurrent pituitary tumors. Asymptomatic, nonfunctioning pituitary adenomas may be followed without any intervention, but surgery is typically indicated if there are symptoms of mass effect on the optic chiasm or endocrine dysfunction.

<< Previous
Treatment of spinal cord tumors

Next >>
Overview of evaluation and treatment guidelines for epilepsy

E2F1 Induces Pituitary Tumor Transforming Gene (PTTG1) Expression in Human Pituitary Tumors
Molecular Endocrinology, 11/02/09 Relevance Score: 69%

Regulation of Pituitary Function by Cytokines
Hormone Research, 10/27/09 Relevance Score: 68%

Medical treatment of Cushing's disease: Overview and recent findings
International Journal of General Medicine, 10/21/09 Relevance Score: 67%

Pituitary metastasis of Merkel cell carcinoma
Journal of Neuro-Oncology, 10/28/09 Relevance Score: 66%

Predicting Recurrence of Nonfunctioning Pituitary Adenomas
Journal of Clinical Endocrinology and Metabolism, 10/15/09 Relevance Score: 66%